Cumberland Change To Inventory vs Free Cash Flow Analysis

CPIX Stock

USD 1.37 0.26 23.42%

Cumberland Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cumberland Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cumberland Pharmaceuticals is a good investment. Please check the relationship between Cumberland Pharmaceuticals Change To Inventory and its Free Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.

Change To Inventory vs Free Cash Flow

Change To Inventory vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cumberland Pharmaceuticals Change To Inventory account and Free Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Cumberland Pharmaceuticals' Change To Inventory and Free Cash Flow is 0.45. Overlapping area represents the amount of variation of Change To Inventory that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Cumberland Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cumberland Pharmaceuticals' Change To Inventory and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Inventory of Cumberland Pharmaceuticals are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Change To Inventory i.e., Cumberland Pharmaceuticals' Change To Inventory and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.45

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Change To Inventory

The increase or decrease in the amount of inventory a company has over a certain period.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Cumberland Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cumberland Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.At this time, Cumberland Pharmaceuticals' Discontinued Operations is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 176.02 in 2024, whereas Selling General Administrative is likely to drop slightly above 8.9 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	98.0K	586.0K	667.9K	701.3K
Depreciation And Amortization	4.6M	5.3M	5.8M	6.1M

Interest Expense Depreciation And Amortization

Cumberland Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Non Currrent Assets Other	Other Liab
Total Assets		0.39	0.52	0.48	0.64	0.09	0.87	-0.23	0.39	0.33	0.5	0.49	0.5	0.49	0.1	0.37	0.54	0.38	-0.09	0.43	0.05	0.75	0.19	0.66	0.18	0.13
Short Long Term Debt Total	0.39		0.68	0.92	-0.44	0.6	0.38	0.69	-0.59	0.83	-0.39	0.87	-0.53	0.75	-0.65	0.99	0.58	0.55	0.17	0.98	0.53	-0.22	-0.16	0.76	0.77	0.89
Other Current Liab	0.52	0.68		0.84	-0.13	0.39	0.49	0.42	-0.24	0.58	-0.24	0.69	-0.24	0.69	-0.45	0.68	0.62	0.31	0.24	0.77	0.35	0.05	-0.12	0.8	0.3	0.54
Total Current Liabilities	0.48	0.92	0.84		-0.34	0.55	0.48	0.67	-0.46	0.86	-0.42	0.93	-0.48	0.82	-0.7	0.92	0.58	0.43	0.33	0.97	0.49	-0.17	-0.05	0.9	0.69	0.81
Total Stockholder Equity	0.64	-0.44	-0.13	-0.34		-0.38	0.53	-0.82	0.85	-0.38	0.87	-0.29	0.96	-0.18	0.68	-0.47	0.02	-0.05	-0.3	-0.42	-0.36	0.94	0.3	-0.05	-0.43	-0.61
Property Plant And Equipment Net	0.09	0.6	0.39	0.55	-0.38		0.41	0.63	-0.76	0.72	-0.39	0.54	-0.48	0.54	-0.62	0.53	-0.02	0.16	0.13	0.55	0.99	-0.31	-0.4	0.3	0.79	0.7
Current Deferred Revenue	0.87	0.38	0.49	0.48	0.53	0.41		-0.1	0.14	0.5	0.4	0.5	0.38	0.51	-0.09	0.33	0.28	0.44	-0.05	0.4	0.41	0.6	0.11	0.57	0.39	0.22
Net Debt	-0.23	0.69	0.42	0.67	-0.82	0.63	-0.1		-0.85	0.74	-0.91	0.64	-0.93	0.4	-0.93	0.69	0.26	0.11	0.56	0.7	0.6	-0.74	-0.36	0.48	0.71	0.88
Retained Earnings	0.39	-0.59	-0.24	-0.46	0.85	-0.76	0.14	-0.85		-0.63	0.73	-0.39	0.87	-0.35	0.76	-0.58	-0.03	-0.21	-0.18	-0.54	-0.75	0.74	0.43	-0.13	-0.69	-0.8
Accounts Payable	0.33	0.83	0.58	0.86	-0.38	0.72	0.5	0.74	-0.63		-0.46	0.8	-0.53	0.73	-0.84	0.8	0.42	0.44	0.34	0.84	0.7	-0.23	0.0	0.71	0.81	0.86
Cash	0.5	-0.39	-0.24	-0.42	0.87	-0.39	0.4	-0.91	0.73	-0.46		-0.42	0.95	-0.15	0.81	-0.42	-0.06	0.13	-0.65	-0.43	-0.37	0.88	0.35	-0.27	-0.47	-0.63
Non Current Assets Total	0.49	0.87	0.69	0.93	-0.29	0.54	0.5	0.64	-0.39	0.8	-0.42		-0.47	0.75	-0.68	0.87	0.42	0.42	0.37	0.92	0.47	-0.21	-0.11	0.91	0.8	0.77
Cash And Short Term Investments	0.5	-0.53	-0.24	-0.48	0.96	-0.48	0.38	-0.93	0.87	-0.53	0.95	-0.47		-0.27	0.82	-0.55	-0.06	-0.04	-0.44	-0.53	-0.46	0.92	0.34	-0.25	-0.59	-0.73
Net Receivables	0.49	0.75	0.69	0.82	-0.18	0.54	0.51	0.4	-0.35	0.73	-0.15	0.75	-0.27		-0.46	0.74	0.33	0.4	0.04	0.79	0.46	-0.02	0.1	0.68	0.57	0.55
Common Stock Shares Outstanding	0.1	-0.65	-0.45	-0.7	0.68	-0.62	-0.09	-0.93	0.76	-0.84	0.81	-0.68	0.82	-0.46		-0.65	-0.21	-0.25	-0.58	-0.68	-0.61	0.62	0.09	-0.57	-0.73	-0.82
Non Current Liabilities Total	0.37	0.99	0.68	0.92	-0.47	0.53	0.33	0.69	-0.58	0.8	-0.42	0.87	-0.55	0.74	-0.65		0.61	0.54	0.18	0.98	0.46	-0.25	-0.18	0.76	0.73	0.89
Inventory	0.54	0.58	0.62	0.58	0.02	-0.02	0.28	0.26	-0.03	0.42	-0.06	0.42	-0.06	0.33	-0.21	0.61		0.27	0.09	0.61	-0.05	0.28	-0.07	0.64	0.09	0.51
Other Current Assets	0.38	0.55	0.31	0.43	-0.05	0.16	0.44	0.11	-0.21	0.44	0.13	0.42	-0.04	0.4	-0.25	0.54	0.27		-0.23	0.5	0.13	0.1	0.11	0.39	0.37	0.38
Other Stockholder Equity	-0.09	0.17	0.24	0.33	-0.3	0.13	-0.05	0.56	-0.18	0.34	-0.65	0.37	-0.44	0.04	-0.58	0.18	0.09	-0.23		0.25	0.13	-0.38	0.03	0.4	0.26	0.29
Total Liab	0.43	0.98	0.77	0.97	-0.42	0.55	0.4	0.7	-0.54	0.84	-0.43	0.92	-0.53	0.79	-0.68	0.98	0.61	0.5	0.25		0.49	-0.22	-0.13	0.84	0.73	0.87
Property Plant And Equipment Gross	0.05	0.53	0.35	0.49	-0.36	0.99	0.41	0.6	-0.75	0.7	-0.37	0.47	-0.46	0.46	-0.61	0.46	-0.05	0.13	0.13	0.49		-0.29	-0.38	0.24	0.75	0.66
Total Current Assets	0.75	-0.22	0.05	-0.17	0.94	-0.31	0.6	-0.74	0.74	-0.23	0.88	-0.21	0.92	-0.02	0.62	-0.25	0.28	0.1	-0.38	-0.22	-0.29		0.3	0.05	-0.4	-0.43
Short Term Debt	0.19	-0.16	-0.12	-0.05	0.3	-0.4	0.11	-0.36	0.43	0.0	0.35	-0.11	0.34	0.1	0.09	-0.18	-0.07	0.11	0.03	-0.13	-0.38	0.3		0.05	-0.27	-0.38
Intangible Assets	0.66	0.76	0.8	0.9	-0.05	0.3	0.57	0.48	-0.13	0.71	-0.27	0.91	-0.25	0.68	-0.57	0.76	0.64	0.39	0.4	0.84	0.24	0.05	0.05		0.54	0.62
Non Currrent Assets Other	0.18	0.77	0.3	0.69	-0.43	0.79	0.39	0.71	-0.69	0.81	-0.47	0.8	-0.59	0.57	-0.73	0.73	0.09	0.37	0.26	0.73	0.75	-0.4	-0.27	0.54		0.83
Other Liab	0.13	0.89	0.54	0.81	-0.61	0.7	0.22	0.88	-0.8	0.86	-0.63	0.77	-0.73	0.55	-0.82	0.89	0.51	0.38	0.29	0.87	0.66	-0.43	-0.38	0.62	0.83

Click cells to compare fundamentals

Cumberland Pharmaceuticals Account Relationship Matchups

Cumberland Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	104.5M	96.5M	84.5M	92.9M	81.8M	88.1M
Short Long Term Debt Total	21.5M	17.1M	16.1M	21.0M	18.4M	11.9M
Other Current Liab	7.7M	9.1M	8.7M	17.6M	13.6M	7.7M
Total Current Liabilities	24.2M	25.7M	19.3M	28.6M	28.0M	16.8M
Total Stockholder Equity	51.1M	47.0M	42.8M	36.3M	29.6M	58.3M
Property Plant And Equipment Net	3.7M	2.6M	1.5M	5.5M	7.0M	7.4M
Net Debt	(6.7M)	(7.7M)	(11.0M)	1.2M	106.9K	112.2K
Retained Earnings	1.2M	(2.1M)	(5.6M)	(11.2M)	(17.5M)	(16.6M)
Accounts Payable	10.0M	13.4M	9.6M	10.8M	14.0M	14.7M
Cash	28.2M	24.8M	27.0M	19.8M	18.3M	27.3M
Non Current Assets Total	54.4M	46.5M	38.8M	47.1M	46.1M	27.5M
Cash And Short Term Investments	28.2M	24.8M	27.0M	19.8M	18.3M	31.1M
Net Receivables	7.9M	12.4M	6.9M	13.2M	9.8M	7.4M
Common Stock Shares Outstanding	15.4M	15.2M	14.9M	14.6M	14.3M	13.5M
Liabilities And Stockholders Equity	104.5M	96.5M	84.5M	92.9M	81.8M	88.1M
Non Current Liabilities Total	29.3M	23.9M	22.6M	28.4M	24.5M	13.1M
Inventory	8.9M	10.6M	8.4M	9.4M	4.6M	7.3M
Other Current Assets	2.8M	2.2M	6.7M	3.1M	3.0M	2.4M
Other Stockholder Equity	2.9M	3.1M	3.4M	(212.3K)	(244.2K)	(256.4K)
Total Liab	53.5M	49.6M	41.9M	57.0M	52.5M	29.9M
Property Plant And Equipment Gross	3.7M	2.6M	1.5M	5.5M	9.3M	9.7M
Total Current Assets	50.2M	50.0M	45.7M	45.9M	35.7M	60.5M
Intangible Assets	30.9M	28.1M	24.0M	30.6M	22.6M	19.2M
Non Currrent Assets Other	18.9M	14.9M	12.5M	10.0M	15.5M	16.3M
Other Liab	8.7M	7.9M	7.5M	7.6M	8.7M	9.2M
Other Assets	18.9M	17.8M	12.5M	10.0M	11.6M	7.4M
Long Term Debt	20M	18.5M	15M	16.2M	12.8M	9.3M
Common Stock	49.9M	49.1M	48.5M	47.5M	47.1M	44.7M
Property Plant Equipment	16.3M	12.2M	1.5M	5.5M	6.3M	6.6M
Net Tangible Assets	19.3M	18.0M	18.0M	4.8M	4.3M	4.1M
Noncontrolling Interest In Consolidated Entity	(198.6K)	(274.3K)	(37.6K)	(117.1K)	(105.4K)	(110.7K)
Common Stock Total Equity	52.4M	51.1M	49.9M	49.1M	44.2M	46.2M
Retained Earnings Total Equity	11.7M	4.7M	1.2M	(2.1M)	(1.9M)	(1.8M)
Long Term Debt Total	9.8M	20M	18.5M	15M	17.3M	10.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Cumberland Stock Analysis

When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cumberland Change To Inventory vs Free Cash Flow Analysis

Change To Inventory vs Free Cash Flow

Change To Inventory vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Change To Inventory

Free Cash Flow

Cumberland Pharmaceuticals fundamental ratios Correlations

Cumberland Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cumberland Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Cumberland Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.98	Short Long Term Debt Total
Total Liab	+ 0.98	Non Current Liabilities Total
Total Liab	+ 0.97	Total Current Liabilities
Cash And Short Term Investments	+ 0.96	Total Stockholder Equity

Common Stock Shares Outstanding	- 0.93	Net Debt
Cash And Short Term Investments	- 0.93	Net Debt
Cash	- 0.91	Net Debt
Retained Earnings	- 0.85	Net Debt
Common Stock Shares Outstanding	- 0.84	Accounts Payable
Other Liab	- 0.82	Common Stock Shares Outstanding